Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
Open Access
- 19 February 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 9 (8), 2643-2652
- https://doi.org/10.1002/cam4.2797
Abstract
Background PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated by anti‐PD(L)‐1. Methods All consecutive patients (pts) enrolled in phase 1 trials with advanced solid tumors and lymphomas treated in phase I clinical trials evaluating monotherapy by anti‐PD(L)‐1 at Gustave Roussy were analyzed. We aimed to assess prevalence and outcome of PSPD across tumor types. We also intended to describe potential clinical and pathological factors associated with PSPD. Results A total of 169 patients treated with anti‐PD(L)‐1 were included in the study. Most frequent tumor types included melanoma (n = 57) and non‐small cell lung cancer (n = 19). At first tumor evaluation 77 patients (46%) presented with immune unconfirmed progressive disease. Six patients (8%) experienced PSPD: 2 patients with partial response; 4 patients with stable disease. Increase in target lesions in the first CT‐scan was more frequently associated to PSPD (67% vs 33%; P = .04). Patients with a PSPD had a superior survival when compared to patients progressing (median OS: 10.7 months vs 8.7 months; P = .07). Conclusions A small subset of PSPD patients may experience response after an initial progression. Assessment of the current strategy for immune‐related response evaluations may require further attention.Keywords
This publication has 29 references indexed in Scilit:
- Nivolumab for Patients With Advanced Melanoma Treated Beyond ProgressionJAMA Oncology, 2017
- Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept studyAnnals Of Oncology, 2017
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialThe Lancet Oncology, 2016
- Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond ProgressionJAMA Oncology, 2016
- Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumabPublished by Elsevier BV ,2016
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010